Abstract Library

#4360 Real-world practice patterns of 177Lu-DOTATATE in neuroendocrine tumours: A GTE national survey

Introduction: 177Lu-DOTATATE is a standard treatment for neuroendocrine tumours. Grade 3/4 hematologic toxicity affects about 5-10% of patients, with a 2-4% risk of secondary malignant hematologic disorders.

Conference:

Presenting Author:

Authors: Oziel-Taieb S, Ansquer C, Deshayes E, Haissaguerre M,

Keywords: 177Lu-DOTATATE, haematological toxicity, thrombocytopenia, neuroendocrine tumour, toxicity management,

#4355 Emergence of DNA damage repair clonal haematopoiesis after peptide receptor radionuclide therapy for neuroendocrine tumours

Introduction: In neuroendocrine tumours (NETs), PRRT (Peptide Receptor Radionuclide Therapy), has shown efficacy but with significant hematologic toxicity. Clonal haematopoiesis (CHIP) is considered a risk factor for therapy-related myeloid neoplasms (t-MN).

Conference:

Presenting Author: Hadoux J

Authors: Loyaux R, Hadoux J, Oziel-Taieb S, Durand A, Bouhier Leporrier K,

Keywords: PRRT, clonal haematopoiesis, DNA Damage Repair, therapy-related myeloid neoplasm, Neuroendocrine tumour,

#3827 Prevalence of Clonal Hematopoiesis (CH) in neuroendocrine tumor (NET) patients prior to Lutetium 177 dotatate therapy (Lu177) and the risk of cytopenia – A prospective study of 37 patients

Introduction: Lu177 has shown efficacy in advanced NET but with significant hematologic toxicity, including therapy-related myeloid neoplasm (t-MN). CH is defined by acquisition of somatic mutations in hematopoietic stem cells with potential for expansion over time.

Conference:

Presenting Author: Sonbol M

Authors: Sonbol M, Kusne Y, Lasho T, Elsabbagh Z, Mangaonkar A,

Keywords: clonal hematopoiesis, neuroendocrine, PRRT, Lu177, t-MN, CHIP,

#3670 Response to peptide receptor radionuclide therapy in pheochromocytomas and paragangliomas – A systematic review and meta-analysis

Introduction: Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC has shown efficacy in the metastatic setting of pheochromocytomas (PCCs) and paragangliomas (PGLs) where no standard therapies have been established.

Conference:

Presenting Author: Marretta A

Authors: Marretta A, Ottaiano A, Iervolino D, Bracigliano A, Clemente O,

Keywords: PRRT, Pheochromocytoma, Paraganglioma, Neuroendocrine Tumor, Meta-analysis,

#3105 Hematotoxicity of Holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial PRRT

Introduction: In patients with neuroendocrine tumor liver metastases, additional tumor reduction can be achieved by sequential treatment with [166Ho]-radioembolization after peptide receptor radionuclide therapy (PRRT).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Ebbers S

Authors: Ebbers S, Brabander T, Tesselaar M, Hofland J, Barentsz M,

Keywords: PRRT, NET, neuroendocrine tumor, neuroendocrine neoplasm, lutetium-177-dotatate, radioembolization, holmium-166, hematologic toxicity,